期刊文献+

药物洗脱球囊对冠状动脉支架内二次再狭窄的临床疗效观察 被引量:4

Clinical efficacy of drug-eluting balloon for re-restenosis in coronary stent
下载PDF
导出
摘要 目的探讨药物洗脱球囊(DEB)对不稳定型心绞痛患者冠状动脉药物洗脱支架(DES)二次再狭窄(ISR)的临床疗效。方法回顾性选取新乡市中心医院心内科2014年6月至2016年6月冠状动脉造影证实支架内二次ISR、并需再次介入治疗的不稳定型心绞痛患者124例,根据治疗方式分为DEB组和DES组,记录两组患者介入治疗术中、术后即刻冠状动脉情况,并随访术后1年冠状动脉造影情况及主要不良心血管事件发生率。结果两组患者基线临床资料差异无统计学意义(均为P> 0. 05),但两组冠状动脉支架内二次ISR病变多位于前降支、表现为局灶型狭窄;两组患者介入前靶血管直径、靶病变最小直径、靶病变长度及靶血管狭窄百分比差异均无统计学意义(均为P> 0. 05),术后即刻靶血管直径和靶病变最小直径差异亦无统计学意义(均为P> 0. 05),但DES组靶血管即刻获得直径和残余百分比明显优于DEB组(均为P <0. 0001)。随访1年,DES组患者的靶病变最小直径、靶病变直径狭窄百分比、晚期管腔直径丢失和晚期管腔直径净获得均优于DEB组(均为P <0. 05),DES组患者晚期管腔直径丢失率明显小于DEB组(P=0. 003),且急性心肌梗死、全因死亡、靶血管血运重建及靶病变再次血运重建率均低于DEB组(均为P <0. 05)。多因素分析发现,高血压、糖尿病、靶病变长度和支架内弥漫型病变是二次ISR的危险因素,而术后靶血管直径是其保护因素。结论 DEB治疗冠状动脉支架内二次ISR的效果不理想,不应作为冠状动脉支架内二次ISR的首选治疗方案,但需更多研究证实。 Objective To investigate the clinical efficacy of drug-eluting balloon(DEB)in coronary artery drug-eluting stent(DES)re-restenosis in patients with unstable angina pectoris(UAP).Methods A total of 124 UAP patients were enrolled into this study in Cardiology Department of Xinxiang Central Hospital from June of 2014 to June of 2016,who underwent DES-in-stent re-restenosis.According to the treatment,patients were divided into DEB group and DES group.Operative and post-operative data of all patients and major adverse cardiovascular events were recorded by coronary angiography in-hospital and after 1-year followed up. Results There was no significant difference in baseline clinical characteristic of two groups(P>0.05).Most common lesion for in-stent re-restenosis were in left anterior descending artery,presenting as focal lesion.Pre-operative target vessel diameter,the minimum diameter of the target lesion,the length of target lesion and the stenosis percentage of target vessel in two groups did not show significant differences(all P>0.05).Post-operative target vessel diameter and immediate minimum diameter of target lesion were not significantly different(both P>0.05),however immediate diameter of target vessel and residual percentage of target lesion was significantly higher in DES group than in DEB group(both P<0.0001).After 1-year follow-up,minimum diameter of target lesion,stenosis percentage of target lesion,late-loss of lumen diameter and late net gain of lumen diameter was significantly higher in DES group than in DEB group(all P<0.05).Late-loss rate of lumen was significantly smaller in DES group than in DEB group(P=0.003).Acute myocardial infarction,all-cause death,target vessel revascularization and target lesion revascularization rate in DES group were less than that in DEB group(all P<0.05).Multifactor analysis showed that hypertension,diabetes,the length of target lesion and diffuse type of lesion were the risk factors,while post-operative diameter of target vessel was the protective factor for in-stent
作者 韩明磊 金卫东 刘振 王成 崔佳佳 李艳茹 Han Minglei;Jin Weidong;Liu Zhen;Wang Cheng;Cui Jiajia;Li Yanru(Department of Cardiology,Xinxiang Central Hospital,Xinxiang 453000,China)
出处 《中国心血管杂志》 2018年第5期389-393,共5页 Chinese Journal of Cardiovascular Medicine
关键词 药物洗脱球囊 药物洗脱支架 支架内再狭窄 二次再狭窄 Drug-eluting balloon Drug-eluting stents In-stent resteonsis Re-restenosis
  • 相关文献

参考文献2

二级参考文献15

  • 1Grewe PH, Deneke T, Machraoui A, et al. Acute and chronictissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coil Cardiol, 2000, 35 : 157-163. 被引量:1
  • 2Speidel CM,Eisenberg PR, Ruf W, et al. Tissue factor mediates prolonged procoagulant activity on the luminal surface of ballooninjured aortas in rabbits. Circulation, 1995, 92: 3323-3330. 被引量:1
  • 3xJoner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans : delayed healing and late thrombotic risk. J Am Coil Cardiol, 2006, 48: 193-202. 被引量:1
  • 4Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation, 1999, 99: 44- 52. 被引量:1
  • 5Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation, 1998, 98 : 224-233. 被引量:1
  • 6Mori T, Kinoshita Y, Watanabe A, et al. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol, 2006, 58: 665-672. 被引量:1
  • 7Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J, 2003, 24 : 1462-1467. 被引量:1
  • 8Scheller B,Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coil Cardiol, 2003, 42: 1415-1420. 被引量:1
  • 9Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation, 2004, 110 : 810-814. 被引量:1
  • 10Speck U,Scheller B, Abramjuk C, et al. Restenosis inhibition by non-stent-based local drug delivery: comparison of efficacy to a drug eluting stent in the porcine coronary overstretch model. Radiology, 2006, 240 : 411-418. 被引量:1

共引文献5

同被引文献41

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部